Eli Lilly (LLY) Hits Highs After FDA Approves Its Alzheimer’s Treatment
Eli Lilly (LLY) hit a new all-time high today as the FDA approved its Alzheimer’s treatment “Kisunla.” The treatment is intended for adults in early symptomatic stages of Alzheimer’s disease.